title: Experience with intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: dose considerations.
abstract: We sought to identify factors influencing dose maintenance of intracavernous (IC) injection among patients with ED following radical prostatectomy. A total of 93 patients underwent prostatectomy and received IC treatment for ED, including PGE1 single therapy (n=53) and triple therapy (n=40). In the PGE1-only group, the maintenance dosage was significantly correlated with preoperative sexual function and nerve sparing (NS) (P<0.05). For example, the maintenance dose among patients with no, unilateral and bilateral NS was 10.8 ± 6.6 μg (0.54 ± 0.33 ml), 10.8 ± 3.8 μg (0.54 ± 0.19 ml) and 6.4 ± 4.6 μg (0.32 ± 0.23 ml), respectively. In terms of preoperative sexual function, the maintenance dose among non-ED versus ED patients was 0.38 ± 0.25 ml (7.6 ± 5.0 μg) and 0.59 ± 0.31 ml (11.8 ± 6.2 μg), respectively. No significant correlation was observed between the maintenance dose and NS or preoperative sexual function among the triple-therapy patients or between the maintenance dose and age, body mass index, systemic diseases and initiation of ED treatment among all patients (P>0.05). Thus, maintenance dose of PGE1 therapy could be partly determined by NS status and prior ED of patients.
authors.affiliation: Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, OH, USA. gu20288@gmail.com
authors.forename: F-P
authors.initials: FP
authors.lastname: Chuang
authors.forename: M
authors.initials: M
authors.lastname: Lakin
authors.forename: S-T
authors.initials: ST
authors.lastname: Wu
authors.forename: T-L
authors.initials: TL
authors.lastname: Cha
authors.forename: G-H
authors.initials: GH
authors.lastname: Sun
authors.forename: D K
authors.initials: DK
authors.lastname: Montague
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage; D000527:Alprostadil / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000209:etiology / Q000628:therapy*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage; D010646:Phentolamine / Q000008:administration & dosage; D011468:Prostatectomy / Q000009:adverse effects; D012189:Retrospective Studies; D014665:Vasodilator Agents / Q000008:administration & dosage*
chemical_list: D000317:Adrenergic alpha-Antagonists; D014665:Vasodilator Agents; D010208:Papaverine; D000527:Alprostadil; D010646:Phentolamine